

May 26, 2017

**Bombay Stock Exchange Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai - 400 001**

Dear Sir/Madam,


Sub: Press Release

Please find enclosed the Press Release issued in connection with Audited Financial Results of the Company for the year ended 31st March, 2017.

Kindly take it on your records.

Thanking you,

Yours faithfully,


L Chandrasekar
Executive VP – Finance & Secretary.

Encl.: a/a



BSE: 524372 NSE: ORCHIDPHAR Bloomberg: OCP@IN Reuters: ORCD.BO

FY17 Earnings

Chennai, India – May 26, 2017

Orchid Pharma registers turnover of Rs. 766 crore in FY17

Financial highlights for year ended March 31, 2017 (FY17) - Standalone.

Revenue of Rs 766 crore [US\$ 117.4 million] registered during the year ended March 31, 2017 (FY 17) as compared to Rs 890 crore [US\$ 136.3 million] registered during the corresponding year ended March 31, 2016.

Earnings before Interest, Depreciation and Tax (EBIDTA) stood at Rs 112 crore [US\$ 17.1 million] for the fiscal under review compared to Rs 198 crore [US\$ 30.4 million] registered during FY16

Net (Loss) for the fiscal ended March 31, 2017 stood at Rs (484) crore [US\$ (74.1) million] compared to a loss of Rs (274) crore [US\$ (42.0) million] for the previous fiscal.

EPS for the fiscal ended March 31, 2017 stood at Rs. (44.67)

*** 1 US\$ = Rs 65.30**

For ORCHID PHARMA LTD.


Executive VP - Finance & Secretary

‘Orchid Towers’, #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA